Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
Revenues from Narcan (naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan due to the launch of over-the-counter Narcan in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.On Thursday, Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
週四，緊急生物解決方案股份有限公司(NYSE:EBS)股票在非洲進行新的mpox試驗，第三季度收益不及預期，因此股價有所上漲。
The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265 million–$315 million, and missing the consensus of $297.5 million.
公司報告第三季度銷售額爲29380萬美元，同比增長9%，管理層預測範圍爲26500萬–31500萬美元，低於29750萬美元的共識。
The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago, beating the consensus of $0.14.
公司報告調整後每股收益爲1.37美元，較一年前的虧損1.09美元有所好轉，超過0.14美元的共識。
Revenues from Narcan (naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan due to the launch of over-the-counter Narcan in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.
Narcan(納洛酮鹽鼻噴霧)的收入下降33%，至9530萬美元，主要是由於處方Narcan的中止導致2023年第三季度場外交易Narcan的推出以及加拿大零售銷售下降，部分抵消了場外交易Narcan的銷售增加。
Also Read: Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines
另請參閱：Emergent BioSolutions確認與天花、mpox疫苗相關的價值40000萬美元的訂單
Revenues from Anthrax MCM fell 65% to $11.4 million, and Smallpox MCM sales jumped more than fivefold to $132.7 million.
炭疽MCm的收入下降65%，至1140萬美元，天花MCm的銷售額增加了五倍以上，達到13270萬美元。
Guidance: Emergent BioSolutions updated its 2024 revenue guidance from $1.05 billion – $1.125 billion to $1.065 billion – $1.125 billion, compared to the consensus of $1.123 billion.
指導：緊急生物解決方案將2024年營業收入指導從10.5億美元–11.25億美元更新爲10.65億美元–112.5億美元，而市場共識爲11.23億美元。
The updated guidance includes commercial product sales of $420 million – $430 million compared to prior guidance of $450 million – $480 million.
更新後的指導包括商業產品銷售額爲42000萬美元–43000萬美元，而之前的指導爲45000萬美元–48000萬美元。
MCM Product sales outlook of $510 million – $550 million, compared to $455 million – $490 million expected earlier.
MCm產品銷售預期爲55000萬美元，而先前預期爲45500萬美元。
Services segment sales are expected to be $105 million – $110 million, lower than the prior range of $120 million – $130 million.
服務部門銷售預計爲10500萬美元，低於先前的13000萬美元區間。
The company expects a 2024 net loss of $203 million – $183 million, compared to the previous loss range of $314 million – $274 million, and an adjusted EBITDA of $180 million – $200 million compared to previous forecast of $140 million – $180 million.
公司預計2024年淨虧損爲20300萬美元，而先前虧損區間爲31400萬美元，調整後的EBITDA爲18000萬美元，而先前預測爲14000萬美元。
Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention.
同時，緊急生物解決方案公司宣佈，布林西多福韋（商標名稱Tembexa，用於天花治療）將被納入由PANTHER主導、由非洲疾病控制和預防中心贊助的試驗中。
The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
該研究將評估布林西多福韋在治療小痘病毒中的安全性和有效性。試驗定於未來幾周在剛果民主共和國及鄰國開始。
Price Action: EBS stock is up 28.3% at $11.80 at last check Thursday.
股票價格走勢：EBS股價上漲28.3%，至11.80美元，截至週四最後檢查時。
Photo via Shutterstock
圖片來自shutterstock
- Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals
- 拉夫勞倫股價飆升，第二季度業績超出預期——CEO瞄準提高營業收入目標的假日季節。
